Daniel J. Lenihan et al. BTS 2016;1:

Slides:

Advertisements

Similar presentations

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB

Advertisements

Safety Reporting IN Clinical Trials

ADVERSE EVENT REPORTING

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release.

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI

Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.

Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center

The EINSTEIN EXT Study 'Xarelto' for the Long-Term Prevention of Recurrent Venous Thromboembolism.

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

Programme Case Studies

Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.

SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.

Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.

Jasper Ogwal-Okeng Gulu University Research Workshop 3 rd -6 th March 08.

Adaptive designs as enabler for personalized medicine

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.

Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.

Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: Pooled Safety Analysis from Seven Studies Diéras V et al. Proc SABCS 2012;Abstract P

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Process of FDA New Drug Approval: 1- New Compound with promising preclinical data 2- Sponsor applies to FDA for an IND (Investigational New Drug Application)

Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

INPULSIS® trial design and baseline characteristics

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib Telli ML, Witteles RM, Fisher GA, Srinivas S. Reviewed by:

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.

What is a Data and Safety Monitoring Plan and how do I get one?

Vahdat L et al. Proc SABCS 2012;Abstract P

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

Jennifer S. Novia INFO 643 March 6, 2011

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Daniel J. Lenihan et al. BTS 2016;1:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

SERIOUS ADVERSE EVENTS REPORTING

FDA Medical Device Approval Pathways

Vesole DH et al. Proc ASH 2010;Abstract 308.

Long-term Data: INPULSIS®-ON

Daniel J. Lenihan et al. BTS 2016;1:

Relative risk of major events with atenolol vs placebo

Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple.

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

AGENT III: 12 week results

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Our goals in using DAWN MPD software in our nurse-led clinic -

Daniel J. Lenihan et al. BTS 2016;1:

Brian D. Williamson et al. JACEP 2017;3:

G. Michael Felker et al. JCHF 2014;2:

Challenges in design and interpretation of chronic pain trials

Guidelines for Initiation of Therapy

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

A) Total Asthma Quality of Life Questionnaire (AQLQ) score over 12 months after treatment with bronchial thermoplasty (BT) in the per protocol population.

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Sources of health outcomes data used in the SJLIFE study where severity grading criteria of long-term and late-onset health events were applied. Sources.

Presentation transcript:

Daniel J. Lenihan et al. BTS 2016;1:576-586 Treatment Algorithm DLT is defined as 1 of the following events deemed to be at least possibly related to study drug: 1) grade III toxicity or above (would encompass life-threatening events); 2) liver function abnormalities as defined in protocol; or 3) other events clinically judged to necessitate dose reductions. If a DLT occurs in the dose reduction step, the decision on whether to stop the study or to continue (reducing the dose by 1 additional dose level) will be made by sponsor and the principal investigator in consultation with the DSMB. DLT = dose-limiting toxicity; DSMB = Data Safety Monitoring Board; GGF = glial growth factor; PBO = placebo. Daniel J. Lenihan et al. BTS 2016;1:576-586 The Authors